236 related articles for article (PubMed ID: 9862681)
1. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
[TBL] [Abstract][Full Text] [Related]
2. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
[TBL] [Abstract][Full Text] [Related]
3. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
4. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
Gajewski TF; Fallarino F; Uyttenhove C; Boon T
J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411
[TBL] [Abstract][Full Text] [Related]
5. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
Yang G; Hellström KE; Hellström I; Chen L
J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
[TBL] [Abstract][Full Text] [Related]
6. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA
J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448
[TBL] [Abstract][Full Text] [Related]
7. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
[TBL] [Abstract][Full Text] [Related]
8. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
Prell RA; Kerkvliet NI
J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803
[TBL] [Abstract][Full Text] [Related]
9. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.
Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE
Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
[TBL] [Abstract][Full Text] [Related]
11. Disruption of CD154:CD40 blocks generation of allograft immunity without affecting APC activation.
Shepherd DM; Kerkvliet NI
J Immunol; 1999 Sep; 163(5):2470-7. PubMed ID: 10452982
[TBL] [Abstract][Full Text] [Related]
12. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
[TBL] [Abstract][Full Text] [Related]
13. Immunogene therapy against mouse leukemia using B7 molecules.
Takahashi T; Hirano N; Takahashi T; Chiba S; Yazaki Y; Hirai H
Cancer Gene Ther; 2000 Jan; 7(1):144-50. PubMed ID: 10678367
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
[TBL] [Abstract][Full Text] [Related]
15. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
16. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
Townsend SE; Su FW; Atherton JM; Allison JP
Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
[TBL] [Abstract][Full Text] [Related]
17. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo.
Sigal LJ; Reiser H; Rock KL
J Immunol; 1998 Sep; 161(6):2740-5. PubMed ID: 9743331
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.
Nakajima A; Kodama T; Morimoto S; Azuma M; Takeda K; Oshima H; Yoshino S; Yagita H; Okumura K
J Immunol; 1998 Aug; 161(4):1901-7. PubMed ID: 9712059
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
[TBL] [Abstract][Full Text] [Related]
20. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
Fields PE; Finch RJ; Gray GS; Zollner R; Thomas JL; Sturmhoefel K; Lee K; Wolf S; Gajewski TF; Fitch FW
J Immunol; 1998 Nov; 161(10):5268-75. PubMed ID: 9820499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
